Atopic dermatitis: Phototherapy and systemic therapy

Dawn Marie Davis*, Jenna Borok, Jeremy Udkoff, Peter Lio, Jonathan Spergel

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The majority of atopic dermatitis (AD) patients respond satisfactorily to gentle bathing, frequent moisturizing, and topical medications. Second-line therapies for AD should be used in recalcitrant cases or in patients with uncontrolled disease despite compliance with first-line measures and avoidance of allergens. Recommended advanced therapies include phototherapy, especially narrowband ultraviolet B, systemic immunosuppressants, and a new biologic agent. Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. Therefore, the agent used is based on provider and patient preferences and can be decided on a case-by-case basis.

Original languageEnglish (US)
Pages (from-to)118-123
Number of pages6
JournalSeminars in cutaneous medicine and surgery
Volume36
Issue number3
DOIs
StatePublished - Sep 1 2017

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Fingerprint Dive into the research topics of 'Atopic dermatitis: Phototherapy and systemic therapy'. Together they form a unique fingerprint.

  • Cite this